Day: October 30, 2022

The European canSERV project – which aspires to defragment the landscape of European cancer research – commences in Brussels today. Over the next three years, canSERV will enable academia and industry access to services and support from basic science up to clinical translation. The initiative aims to foster personalised medicine for cancer patients. All services of the participating infrastructures will be linked on a common platform which will go online within the next few months. canSERV will connect, coordinate and align existing oncology and complementary research infrastructures alongside providing services in a synergistically. This will capitalise on the critical mass

Data further supports the continued development of FLU-v as a broad-spectrum influenza vaccine Open Orphan – a company that tests infectious and respiratory disease products in human challenge clinical trials – has announced positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v. The vaccine is Imutex’s broad spectrum influenza vaccine. Previous clinical studies have demonstrated that FLU-v induced increased antibody and cellular responses in vivo. This placebo-controlled study evaluated the ability of FLU-v to induce cellular effector functions and cross-reactivity. Both are measures of the immune response, with cross-reactivity being particularly important for protection against multiple

Study involves patients with advanced common cancers and solid tumours Exelixis has announced promising initial results from the ongoing dose-escalation stage of JEWEL-101 – a phase 1 study evaluating XB002, the company’s next-generation tissue factor-targeting antibody-drug conjugate. The data was presented at ENA 2022 during the Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research. JEWEL-101 has enrolled several patients with advanced solid tumours for which therapies are unavailable, ineffective or intolerable. The most common types of cancer for these